FindMyKOL
Clinical trialNCT00344019TerminatedPhase 4Interventional

Effects of Atorvastatin on Myonecrosis

NCT00344019 is a phase 4 interventional trial sponsored by Beth Israel Deaconess Medical Center. As of 21 Nov 2026, it was terminated. It studies Atorvastatin and Placebo in Coronary Disease. The registry lists an enrollment of 97 participants at 1 site in 1 country. The registry lists a start date of 31 May 2006 and a primary completion date of 31 Oct 2008.

View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00344019
FieldValue
Registry IDNCT00344019
StatusTerminated
PhasePhase 4
Study typeInterventional trial
Lead sponsorBeth Israel Deaconess Medical Center
Enrollment97
Registered sites1
Countries1
ConditionsCoronary Disease
DrugsAtorvastatin and Placebo
Start31 May 2006
Primary completion31 Oct 2008
Study completion31 Jan 2009
Last update posted2 Jan 2018

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is designed as a prospective, randomized, placebo-controlled, double-blind analysis of atorvastatin 80 mg versus placebo administered on average 4 hours prior to percutaneous coronary intervention \[PCI\] (at least 2 hours) in patients presenting with unstable angina. Only patients with negative cardiac biomarkers, measured on 2 separate occasions a few hours apart will be eligible for inclusion. Furthermore, patients already on high-dose statin therapy; patients taking any statin within 24 hours prior to the PCI; and patients with contraindications to statins will be excluded from the study. The primary endpoint is a quantitative troponin level at 18-24 hours after PCI. At an enrollment of a total of 150 patients (75 per group), the study is powered to detect a 30% difference in troponin level. Secondary endpoints include elevation of creatine kinase (CK) and CK-MB above the upper limit of normal, change in C-reactive protein (CRP) levels from baseline and thrombolysis in myocardial infarction (TIMI) myocardial perfusion grade. All patients will be started on statin therapy the day after the procedure, as deemed appropriate by their treating physicians.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Massachusetts, United States1 site
  • Beth Israel Deaconess Medical Center

    Boston

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusetts: 1 siteMA1Rhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00344019

Each answer restates registry values shown on this page.

What is NCT00344019?

NCT00344019 is a phase 4 interventional trial sponsored by Beth Israel Deaconess Medical Center. It studies Atorvastatin and Placebo in Coronary Disease.

Who leads NCT00344019?

The registry names Joseph Carrozza, Jr, MD (principal investigator, Beth Israel Deaconess Medical Center) as the overall official.

Where does NCT00344019 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT00344019 study?

The registered drug and biological interventions are Atorvastatin and Placebo.

When did NCT00344019 end?

The registry lists a primary completion date of 31 Oct 2008 and a study completion date of 31 Jan 2009. The sponsor last updated the record on 2 Jan 2018.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.